Results 21 to 30 of about 14,898 (265)
Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies
Brain Communications, 2020 Variants in the GABRB3 gene encoding the β3-subunit of the γ-aminobutyric acid type A ( receptor are associated with various developmental and epileptic encephalopathies.
N. Absalom +20 more
semanticscholar +1 more source
Vigabatrin and psychosis. [PDF]
Journal of Neurology, Neurosurgery & Psychiatry, 1991 We report a series of 14 cases of psychosis occurring in patients with severe intractable epilepsy, following the prescription of vigabatrin, a new antiepileptic drug. Nine patients had no previous history of psychosis. In eight patients the psychosis occurred following a change in the habitual pattern of seizure activity; in four it developed after a ...
Simon Shorvon +3 more
openaire +2 more sources
Epilepsia, 1999 Summary:Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter γ‐amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA‐transaminase. This produces an increase in central nervous system (CNS) GABA levels.
openaire +3 more sources
Vigabatrin and depression. [PDF]
Journal of Neurology, Neurosurgery & Psychiatry, 1993 Ten patients who developed a major depressive episode in association with vigabatrin treatment for intractable epilepsy are reported. The depression usually occurred early in the course of treatment, but when delayed followed a recent increase in dose. Depressive symptoms occurred at doses varying between 1.5 g and 4 g a day, often but not always when ...
E. H. Reynolds +3 more
openaire +3 more sources
Vigabatrin add-on therapy for drug-resistant focal epilepsy.
Cochrane Database of Systematic Reviews, 2020 BACKGROUND This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to
Rebecca Bresnahan +4 more
semanticscholar +1 more source
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1996 ABSTRACT:Vigabatrin (VGB) is a recently-released antiepileptic drug which works by a clearlydefined mechanism of action: inhibition of GABA transaminase leading to an elevation of brain GABA concentration. It has been proven effective, mainly as an add-on agent, in complex partial and secondarily generalized seizures in both adults and children as well
openaire +2 more sources
Epilepsia, 2009 SummaryVigabatrin (VGB) is a structural analogue of γ‐aminobutyric acid (GABA) that irreversibly inhibits GABA‐transaminase (GABA‐T), increasing brain levels of GABA. VGB is under assessment for treatment of infantile spasms (IS) and refractory complex partial seizures (CPS). Response can be rapid with spasm cessation following approximately 2 weeks of
L. James Willmore +4 more
openaire +3 more sources
, 2018 Vigabatrin is a second-generation antiepileptic drug characterized by a few antiepileptic indications, with a very good interaction profile in polytherapy. Clinically relevant adverse effects (especially visual field defects) have reduced its use as antiepileptic drug in routine clinical practice considerably.
C. Vidal, W.-R. Külpmann
openaire +3 more sources
Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy. [PDF]
, 2015 Retinal nerve fibre layer (RNFL) thickness is related to the axonal anterior visual pathway and is considered a marker of overall white matter 'integrity'. We hypothesised that RNFL changes would occur in people with epilepsy, independently of vigabatrin
Acheson, J +11 more
core +1 more source
Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms [PDF]
, 2010 Jason T Lerner1, Noriko Salamon2, Raman Sankar1,31Departments of Pediatrics, 2Radiological Sciences, 3Neurology, David Geffen School of Medicine, University of California Los Angeles and Mattel Children’s Hospital at UCLA, Los Angeles, CA ...
Jason T Lerner +2 more
core +3 more sources